Clinical Trial Detail

NCT ID NCT03325166
Title Pembrolizumab and Magnetic Resonance Imaging With Ferumoxytol in Treating Patients With Non-small Cell Lung Cancer and Brain Metastases
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors OHSU Knight Cancer Institute
Indications

lung non-small cell carcinoma

Therapies

Pembrolizumab

Age Groups: adult senior

No variant requirements are available.